Aurisco Pharmaceutical Co. Ltd. Class ASSE: 605116

"Aurisco Pharmaceutical Co., Ltd."Announcement on Obtaining Notice of Approval for Drug Supplementary Application by a Wholly-owned Subsidiary

Aug 25, 2026 · Issued by Aurisco Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange

Announcement on Obtaining Notice of Approval for Drug Supplementary Application by a Wholly-owned Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Aurisco Pharmaceutical Co. Ltd. Class A

"Aurisco Pharmaceutical Co., Ltd."Announcement on the Wholly-owned Subsidiary Passing the U.S. FDA On-Site InspectionAug 13
"Aurisco Pharmaceutical Co., Ltd."Announcement on the Proposed Selection of the Company's Products in the 12th Batch of National Centralized Drug ProcurementAug 4
"Aurisco Pharmaceutical Co., Ltd."Announcement on 2026 Interest Payment for "Aurisco Convertible Bonds"Jul 21
"Aurisco Pharmaceutical Co., Ltd."Announcement on Inclusion of the Company's Main Products in the "National Essential Medicines List (2026 Edition)"Jul 16

All Aurisco Pharmaceutical Co. Ltd. Class A news releases